JP2013528622A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528622A5
JP2013528622A5 JP2013513360A JP2013513360A JP2013528622A5 JP 2013528622 A5 JP2013528622 A5 JP 2013528622A5 JP 2013513360 A JP2013513360 A JP 2013513360A JP 2013513360 A JP2013513360 A JP 2013513360A JP 2013528622 A5 JP2013528622 A5 JP 2013528622A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cadherin
optionally
composition according
der
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013513360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528622A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/039002 external-priority patent/WO2011153397A2/en
Publication of JP2013528622A publication Critical patent/JP2013528622A/ja
Publication of JP2013528622A5 publication Critical patent/JP2013528622A5/ja
Pending legal-status Critical Current

Links

JP2013513360A 2010-06-04 2011-06-03 炎症性障害の処置 Pending JP2013528622A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35150510P 2010-06-04 2010-06-04
US61/351,505 2010-06-04
PCT/US2011/039002 WO2011153397A2 (en) 2010-06-04 2011-06-03 Treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2013528622A JP2013528622A (ja) 2013-07-11
JP2013528622A5 true JP2013528622A5 (enExample) 2014-07-24

Family

ID=45067307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513360A Pending JP2013528622A (ja) 2010-06-04 2011-06-03 炎症性障害の処置

Country Status (7)

Country Link
US (1) US20130209476A1 (enExample)
EP (1) EP2575883B1 (enExample)
JP (1) JP2013528622A (enExample)
AU (1) AU2011261323A1 (enExample)
CA (1) CA2805270C (enExample)
IL (1) IL223385B (enExample)
WO (1) WO2011153397A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130068691A1 (en) * 2011-08-05 2013-03-21 Henry John Smith Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders
WO2016100301A1 (en) * 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
US20200181649A1 (en) * 2016-07-14 2020-06-11 University Of Delaware Hybrid formulation of responsive polymeric nanocarriers for therapeutic and diagnostic delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US7481999B2 (en) * 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
CN101613405A (zh) * 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
MXPA05011409A (es) * 2003-04-23 2005-12-12 Medarex Inc Composiciones y metodos para la terapia de enfermedad inflamatoria intestinal.
US20050002919A1 (en) * 2003-06-09 2005-01-06 The Brigham And Women's Hospital, Inc. Cadherin directed molecular and cellular localization
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
WO2008140774A2 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
WO2009101059A2 (en) * 2008-02-11 2009-08-20 Novartis Ag Methods of using cadherin 11 (cdh11) antagonists
US8802687B2 (en) * 2009-02-09 2014-08-12 Georgetown University Cadherin-11 inhibitors and methods of use thereof
US8877188B2 (en) * 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
CA2805267C (en) * 2010-05-04 2019-07-30 The Brigham And Women's Hospital, Inc. Detection and treatment of fibrosis

Similar Documents

Publication Publication Date Title
Yang et al. Targeting HMGB1 in inflammation
Fanelli et al. Neuromuscular blocking agent cisatracurium attenuates lung injury by inhibition of nicotinic acetylcholine receptor-α1
Kuang et al. Vascular endothelial S1pr1 ameliorates adverse cardiac remodelling via stimulating reparative macrophage proliferation after myocardial infarction
Park et al. Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats
Matsumoto et al. CD44 expression in astrocytes and microglia is associated with ALS progression in a mouse model
Yang et al. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats
ES2940239T3 (es) Tratamiento de enfermedades autoinmunitarias con combinaciones de agonistas de RXR y hormonas tiroideas
NZ599315A (en) Antibody therapeutics with local activity in the digestive tract
Momcilović et al. CXCL12 in control of neuroinflammation
Liu et al. Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix
US20230129866A1 (en) Methods of treating respiratory disease with deupirfenidone
WO2021183774A1 (en) Treating acute respiratory distress
JP2013528622A5 (enExample)
Rakhimova DEVELOPMENT OF CARDIORENAL SYNDROME IN PATIENTS WITH ARTERIAL HYPERTENSION
Garcia-Dorado et al. Primary results of the PROMISE trial: myocardial protection with intracoronary adenosine given before reperfusion in patients with STEMI
Govaert et al. Poor functional recovery after transplantation of diabetic bone marrow stem cells in ischemic myocardium
Antonelli et al. Year in review in Intensive Care Medicine 2012: I. Neurology and neurointensive care, epidemiology and nephrology, biomarkers and inflammation, nutrition, experimentals
CN106714842A (zh) 包含双重PI3K δ‑γ激酶抑制剂和皮质类固醇的治疗方法及组合物
Ai et al. Paeonol ameliorates diabetic nephropathy by promoting TFEB-mediated lysosome biogenesis and lipophagy
WO2023001305A1 (zh) 缓解或治疗纤维化性疾病的药物组合物或药盒及其应用
CN104644620B (zh) 化合物xl‑001在制备治疗慢性肾脏病的药物中的用途
Pugliese et al. Hypoxic pulmonary hypertension
JP2014079188A (ja) 無菌性慢性前立腺炎非ヒトモデル動物、頻尿非ヒトモデル動物およびこれらを用いた被験物質の評価方法
Thachil The lung megakaryocytes and pulmonary fibrosis in systemic sclerosis
Suda et al. Spherical sulfated cellulose adsorbs high-mobility-group box chromosomal protein 1 in vitro and in vivo